Announcements

Via Oncology Pathways
Earlier this week, Smilow Cancer Hospital launched Via Oncology’s Clinical Pathways to help to standardize care across Smilow and prioritize clinical trials when they are available for our patients. Via initially launched in medical oncology, gynecological oncology, and hematology. This decision support tool is based on evidence-based guidelines and is customized to include our clinical trials. If you have not already done so, I encourage all providers to sign up for training to learn more about the tool and to become familiar with the platform. Training sessions are offered on our main campus and at our care centers. If you have questions on the implementation, please contact Kerin Adelson. To schedule training, please contact Andrea Kliss.

6th Annual Symposium on Global Cancer Research
The 6th Annual Symposium on Global Cancer Research will be held in New York City on March 15, 2018, prior to the start of the 9th Annual Consortium of Universities for Global Health Global Health Conference. Dr. Anees Chagpar, Assistant Director for Global Oncology for Yale Cancer Center, is assisting in the planning for the Symposium and would like to encourage Yale Cancer Center members to submit abstracts for consideration. Please consider submitting your research by December 12 to the planning committee.

The objectives of this full-day Symposium on Global Cancer Research are to provide: (1) A comprehensive overview of the role of research in addressing local and global disparities in cancer care and control; (2) A stimulating and engaging forum for knowledge sharing; and (3) An environment that facilitates new collaborations to advance...
our knowledge and practice aimed at overcoming cancer disparities.

Learn More >>

**ESPN is Living Smart**

Yale Cancer Center and Smilow Cancer Hospital have partnered with ESPN to provide educational programming and cancer screenings to their employees during their Living Smart wellness series this fall. In October, Dana Shaffer and four volunteer Reiki practitioners gave introductory Reiki sessions to employees. Last week, Melinda Irwin, PhD, MPH and Xavier Llor, MD gave presentations on “The role of exercise and nutrition in preventing and controlling cancer” and “Is cancer predisposition in my genes?” Earlier this week, Yale Dermatology’s team from their Middlebury office provided skin cancer screenings to employees. And on November 16, our head and neck cancers team will be giving screenings. Thank you to everyone who has dedicated their time to bring our cancer education and prevention to their employees in Bristol!

Early Screening for Lung Cancer?
Many people are not aware you can be tested for the disease

Read More >>

Promising Yale cancer research supported by Stamford based non-profit leading charge in gene therapy studies

Read More >>

Scholars Take a Deep Dive into Tissue Imaging Mass Spectrometry

Read More >>

**Lung Cancer Living Room**

Yale Cancer Center and Smilow Cancer Hospital kicked off Lung Cancer Awareness Month last night with Bonnie Addario and the Lung Cancer Foundation during a “living room” discussion of lung cancer at Yale University’s Kroon Hall with a panel from our Thoracic Oncology Program. The talk show style event was hosted by Bonnie and included
discussion with the panelists and many questions from our audience of patients and family members.

Notables

Melinda Irwin, PhD, MPH, Associate Director for Population Sciences at Yale Cancer Center, has been appointed Vice Chair of the SWOG Survivorship Committee.

Terri Parker, MD, Assistant Professor of Medicine (Hematology) has been selected to participate in the American Society of Hematology (ASH) Ambassador Program. The ASH Ambassador Program is designed to support the recruitment and retention of the next generation of hematologists.

Brian Shuch, MD, Assistant Professor of Urology, recently returned from a trip to Shanghai, China, where he visited Renji Hospital and Shanghai Jiao Tong University School of Medicine to establish collaboration on hereditary kidney cancer.

Nikhil Joshi, PhD, a member of Yale Cancer Center’s Cancer Immunology Research Program, received a scientific research grant from the Lung Cancer Research Foundation to support his project, Investigating anti-tumor T cell function in autochthonous models of lung adenocarcinoma.

Can Digestive Chemistry Uncover Sex-Specific Causes of Colon Cancer?

Join Yale Cancer Center on Facebook

LATEST POSTS:

Yale Dermatology visited ESPN yesterday to provide skin cancer screenings to their employees. Thank you to the Yale Dermatology team from Middlebury, CT for spending their day at ESPN and providing screenings! #earlydetection

November is Lung Cancer Awareness Month. Lung cancer is the leading cause of cancer deaths in the United States, with an estimated 155,870 deaths in 2017. New research is improving the early detection and survival rates for this disease, but there is still so much more to learn.
Development Update

Camille Servodidio, Program Manager, Women's Oncology Services, met with Jim Pino from the band Freeplay, Rex Clayton, Exalted Ruler, Westbrook BPO Elks Club, and volunteer leaders of the 9th annual Beach Jam for Breast Cancer to accept a check representing proceeds from the August event. The support is directed to breast cancer patients requiring supplemental assistance to maintain quality of life.

Employee Profile: Tory Murtha

Building a work culture that encourages and promotes personal and professional growth is important to Tory Murtha, MSN, BSN, OCN, patient services manager for Smilow Cancer Hospital at Saint Francis Hospital (SFH). As a part of the Yale New Haven Health system since 2007 and in her current role since 2015, Tory has been instrumental in

Read More >>

Congratulations to newlyweds Brian and Kathryn Paquette! Brian and Kathryn generously asked their wedding guests to contribute to the Smilow Social Work Fund at their ceremony, in appreciation of the treatment and support Kathryn received as a patient of the Smilow Brain Tumor Program a few years ago. On the happiest day of their lives, she and Brian wanted to help other patients. Thank you, Brian and Kathryn!

Read More >>

Researchers at Yale Cancer Center have recently discovered the molecular mechanism behind the resistance of some lung cancers to a new form of therapy, called immune checkpoint inhibitors. This treatment has significantly impacted the lung cancer landscape, but the majority of tumors still do not respond to the therapy and are classified as resistant—which prompted the study’s investigation.

"Understanding the biology of acquired resistance to these therapies is really
promoting and encouraging her team to aim to be their best.

As the manager of a unit that integrated with Smilow in 2015, Tory co-chairs a multidisciplinary operation council with leaders from SFH and YNHH, working to align standards and practice between the two organizations to enhance oncology care.

Tory's commitment to encouraging personal and professional growth amongst her team has resulted in multiple members enrolling in DNP, APRN, and RN programs. In addition to those furthering their academic education, others are advancing up the nursing clinical ladder after showing increased participation and accountability, and in developing and leading projects. Placing an emphasis on her team has provided a high return on investment as Tory’s department has low turnover and has increased their engagement and Press Ganey scores since her arrival to the unit.

Tory has also been on the receiving end of this same encouragement. Her supervisor, Cathy Lyons RN, MS, NEA-BC, vice president, Patient Services, Smilow Cancer Hospital, nominated Tory for the Nursing Leadership Academy within Yale University School of Management in 2015. The support and guidance she received from her managers inspired her to establish the same culture for her own staff, and she feels this would not have happened without the support of the larger institution.

"It's exciting to be part of the Yale New Haven Health system as the healthcare landscape changes," said Tory. "Being a part of an organization that is willing to step outside of the box, think in unique ways, and always encouraging its employees to be innovators in care. I am fortunate to work with leaders that support this type of mindset at every level."

#OOTBTHANKS

important because this knowledge will allow us to figure out what we need to do to treat resistant tumors," explained Katerina Politi.

In a new piece for MedPage Today, Dr. F. Perry Wilson discusses recent evidence that men may be at greater risk for HPV-related oral cancer than commonly believed. The rate of oropharyngeal cancer caused by HPV is dramatically higher in men than in women, and experts are delving researching more to learn why this is the case and what can be done about it.

Follow Yale Cancer Center on Twitter

LATEST TWEETS:
Dr. Skyler Johnson talks to the Cancer Network about the risks of choosing alternative medicine for treatment. [Link](http://www.cancernetwork.com/astro/greater-risk-death-cancer-patients-who-choose-alternative-therapies ...)

@Joshilabyale Nik receiving the scientific merit award from the @Lung_Fund today in NYC! @YaleCancer

November is Lung Cancer Awareness Month. Read what YCC experts say about getting tested for the disease: [Link](http://bit.ly/2zd7ol3)

Did you know you can be tested for Lung cancer? Yale Cancer Center experts talk about screening for the disease. [Link](http://bit.ly/2zd7ol3)

Our @yalederm team is at @espn to screen employees for skin cancer. #earlydetection#prevention

@KidneyCancerDoc visited Renji Hospital + Shanghai Jiao Tong Univ. School of Medicine to est. a collaboration on hereditary #kidneycancer.

Storm Philippe can't stop Biology off to NYC for the Evotec/Yale F2F DNA Repair meeting @EvotecAG@YaleCancer

@AneesChagpar will talk with breast cancer survivor, Anne-Marie, today on @wnpr at 7:30pm. Tune in to hear her patient perspective. #BCAM

@YaleCancer's Centerpoint Magazine - exciting research & patient stories .@YNHH .@YaleMed.

Talking increased risk of death with alternative medicines for cancer for Yale Cancer Answers broadcast with @jamesbyu Faces MADE for radio!

---

#OOTB: Anne Caldwell

YCC #OUTOFTHEBLUETHANKS recently recognized Anne Caldwell, RN, a Nurse Educator in the Clinical Trials Office, for her remarkable contribution to the many disease teams that she supports. Anne’s commitment to our patients, our clinical trials, and the field of oncology is exceeded only by her compassion and willingness to go the extra mile when someone needs "just one more thing." Thank you, Anne!

#OOTB: Kadisha Recalde and Richard Carr

YCC #OUTOFTHEBLUETHANKS recently recognized Kadisha Recalde, Accountant II, and Richard Carr, Program Manager, for their tremendous contribution with a recent grant submission. Navigating through many obstacles, including the effects of Hurricane Irma, Kadisha and Richard's tireless efforts and dedication enabled their team to get the grant submitted before the deadline. Thank you, Kadisha & Richard!
Yale Cancer Center's #OUTOFTHEBLUETHANKS program is a staff recognition initiative to show appreciation to employees who have exemplified an above-and-beyond effort or an outstanding contribution to the team. All nominations should be submitted to the Director's Office c/o Anna Raso.

Funding Opportunities

Pershing Square Sohn Cancer Research Alliance - 2018 Prize for Young Investigators in Cancer Research
The prize of $200,000 per year for up to three years is awarded annually to at least six New York City area scientists, enabling them to continue to pursue explorative, high-risk/high-reward cancer research at a stage when traditional funding is lacking.  
**Deadline for Letter of Intent:** November 6, 2017  
Learn More >>

Basser Center for BRCA External Research Grant Program
The Basser Center for BRCA at Penn Medicine's Abramson Cancer Center announces the Basser External Research Grant Program, which focuses on projects that have the potential to advance the care of individuals living with BRCA1 and BRCA2 mutations.  
**LOI Due:** November 13, 2017  
Learn More >>

NCCN Young Investigator Award
The NCCN Foundation invites proposals from young investigators with innovative ideas and an interest in improving the quality, effectiveness, and efficiency of care provided to cancer patients. Research projects may pertain to: 1) The application of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®); or 2) Address new prevention, detection or treatment approaches for cancer and its translation into clinical care.

The award is open to physicians, scientists, nurses and others working in an oncology laboratory, clinical research or clinical setting, or cancer control program in one of NCCN's 27 Member Institutions, who: 1) Have a first full-time appointment as an Assistant Professor, Instructor, or an equivalent level, and 2) Are MD's, PhD's or, for nurses and others, have an advanced degree.

1400 on 1400. A tremendous milestone for patients with advanced non-small cell lung cancer  
@YaleCancer@CancerResrch

Looking forward to watching  
@WTNH@jocelynmmaminta tonight at 5:10pm for storyon #cancer#genetherapy  
@YaleCancer@ACGTFoundation

Dr. Lajos Pusztai will discuss Triple Negative Breast Cancer and #Immunotherapy options for Rx today at 7:30pm .@wnpr#TNBC#bcsm#BCAM

Thank you @sistersjourney for welcoming our Screening Program to your annual Pink Tea!  
#earlydetection#Mammography

Closer to Free

Calendar of Events

**November 3; 11:30AM**  
Yale ICSNM Program Lecture Series  
Brady Auditorium  
Mitochondrial Behavior  
Jodi Nunnari, PhD  
Read More >>

**November 5; 7:30PM**  
Yale Cancer Answers  
WNPR
Each NCCN Member Institution can nominate up to two applicants who may submit research applications relating to one or both of the categories of investigation summarized below: 1) Research pertaining to the NCCN Guidelines®; 2) New prevention, detection or treatment approaches for cancer and their translation into clinical care.

Nomination and Application Deadlines: For nomination consideration, please send a short research summary proposal and your CV to Robert Garofalo and Christina Bates by 5:00 PM on Wednesday, November 15, 2017. Two nominations for the NCCN Young Investigator Award will be sent from Yale Cancer Center/Smilow Cancer Hospital. Full applications will need to be submitted to NCCN by January 27, 2018.

Clinical and Epidemiological Research on Chronic Disease in the Caribbean
NCI Center for Global Health (CGH) helps reduce the global burden of cancer by strengthening research capacity through funding and training.

Application Deadline: November 15, 2017
Learn More >>

Program in Innovative Therapeutics for Connecticut's Health (PITCH)
The Program in Innovative Therapeutics for Connecticut's Health (PITCH) fuels target validation based on innovative research ideas born in laboratories from Yale University and the University of Connecticut.

Application Deadline: November 15, 2017
Learn More >>

Basser Center for BRCA External Research Grant Program
The Basser Center for BRCA at Penn Medicine's Abramson Cancer Center announces the Basser External Research Grant Program, which focuses on projects that have the potential to advance the care of individuals living with BRCA1 and BRCA2 mutations.

LOI Due: November 13, 2017
Learn More >>

Clinical and Epidemiological Research on Chronic Disease in the Caribbean
NCI Center for Global Health (CGH) helps reduce the global burden of cancer by strengthening research capacity through funding and training.
Program in Innovative Therapeutics for Connecticut's Health (PITCH)

PITCH fuels target validation based on innovative research ideas born in laboratories from Yale University and the University of Connecticut. This three-year, $10 million dollar program provides translational research resources to generate prototype therapeutics that address unmet clinical needs.

Application Deadline: November 15, 2017
Learn More >>

Melanoma Research Alliance

The Melanoma Research Alliance (MRA) is pleased to announce a Request for Proposals (RFP) for high-impact pre-clinical, translational, and early clinical research that has the potential to lead to near-term clinical application in melanoma prevention, detection, diagnosis, staging, and treatment. This cycle, proposals will be accepted for Team Science Awards, Young Investigator Awards, and Academic-Industry Partnership Awards for Established Investigators.

Application Deadline: November 17, 2017
Learn More >>

Exploratory Grants in Cancer Epidemiology and Genomics Research (R21)

This funding opportunity announcement (FOA) invites applications for research on cancer epidemiology, genomics, and risk assessment.

Application Deadline: November 22, 2017
Learn More >>

Pilot and Feasibility Studies Evaluating the Role of RNA Modifications (the 'epitranscriptome') in Cancer Biology (R21)

This Funding Opportunity Announcement (FOA) encourages basic research into the role of RNA chemical modifications and their corresponding writers, readers and erasers in the initiation and progression of cancer.

Application Deadline: November 22, 2017
Learn More >>
Clinical and Translational Exploratory/Developmental Studies (R21)

This Funding Opportunity Announcement (FOA) supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies—including the use of new clinically-relevant models and imaging technologies—which could lead to first-in-human clinical trials.

**Application Deadline:** November 22, 2017

[Learn More >>]

Emerging Questions in Cancer Systems Biology (U01)

This Funding Opportunity Announcement (FOA) invites cooperative agreement applications for Research Projects that utilize systems biology approaches to address emerging questions in cancer initiation, progression, and treatment.

**Application Deadline:** November 24, 2017

[Learn More >>]

Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (U01)

This Funding Opportunity Announcement (FOA) will support the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research.

**Application Deadline:** November 30, 2017

[Learn More >>]

Lion Heart Fund for Cancer Research

Yale investigators are encouraged to submit proposals of innovative, high-potential projects requiring pilot funding. Projects may be in any area of breast cancer research - basic, translational, clinical, outcomes and population science are all welcomed from any discipline or group of disciplines.

**Proposal Due Date:** December 4, 2017

[Learn More >>]

Cooperative Agreement to Develop Targeted Agents for Use with Systemic Agents Plus Radiotherapy (U01)

---

**November 15; 5:30PM**

**Smilow Research Summit**

Kert D Sabbath, MD; Anne Chiang, MD, PhD; Rogerio C Lilenbaum, MD

[Read More >>]

**November 16; 12:30PM**

**Pathology Grand Rounds**

LMP 1094

*Gut Commensal Translocation in Autoimmunity*

Martin Kriegel, MD, PhD

[Read More >>]

**November 16; 2:30PM**

**Smilow Cancer Genetics and Prevention Program Seminar**

SRC, suites 107-109

[Read More >>]

**Submissions**

Please submit your recent publication and grant announcements to:

**Renee Gaudette**

Director, Public Affairs and Marketing

renee.gaudette@yale.edu

[Forward to a Friend]
The purpose of this Funding Opportunity Announcement (FOA) is to invite cooperative agreement (U01) applications that propose studies to enhance pre-clinical in vitro and in vivo testing of NCI-prioritized molecularly targeted anti-cancer agents for use with radiation therapy combined with systemic chemotherapy.

**Application Deadline:**
December 14, 2017

[Learn More >>](#)

**2018 Catalyst Grant**
Supports a junior faculty to conduct pancreatic cancer research and establish successful career paths in the field with a $500,000 grant over three years. Proposed research may be basic, translational, clinical, or epidemiological in nature and must have direct applicability and relevance to pancreatic cancer.

**Application Deadline:** December 15, 2017

[Learn More >>](#)

**Academic-Industrial Partnerships for Translation of Technologies for Cancer Diagnosis and Treatment (R01)**
This Funding Opportunity Announcement (FOA) encourages applications from research partnerships formed by academic and industrial investigators, to accelerate the translation of technologies, methods, assays or devices, and/or systems for preclinical or clinical molecular diagnosis or in vitro imaging that are designed to solve a targeted cancer problem.

**Application Deadline:**
January 8, 2018

[Learn More >>](#)

**The Howard Hughes Medical Institute - The Hanna H. Gray Fellows Program Competition**
The goal of the Hanna H. Gray Fellows Program is to recruit and retain individuals who are from gender, racial, ethnic, and other groups underrepresented in the life sciences, including those from disadvantaged backgrounds, early in their careers.

**Application Deadline:** January 10, 2018

[Learn More >>](#)

**2018 Transitional Research Grant**
Supports independent investigators conducting high priority pancreatic cancer research that is poised for important
translational next steps with a $500,000 grant over two years. Proposed research should aim to identify novel targets and approaches to the treatment of pancreatic cancer or understand and circumvent treatment resistance.

**Application Deadline:** January 15, 2017

Learn More >>

**Minority Patient-Derived Xenograft (PDX) Development and Trial Centers (M-PDTCs) (U54)**

The main goals for this initiative include: a) Development of racially/ethnically diverse PDX models; b) Development of methods for preclinical testing of single agents and drug combinations; and c) Conducting response studies of PDX models, primarily from racially/ethnically diverse populations, to develop novel therapeutic strategies.

**Application Due Date:** January 18, 2018

Learn More >>

**Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities (P20)**

The goals for this FOA include the development of translational research programs focused upon investigating cancer health disparities.

**Application Due Date:** January 18, 2018

Learn More >>

**Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20)**

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites P20 planning grant applications for developing collaborative partnership between institutions serving underserved health disparity populations and underrepresented students (ISUPS) and NCI- designated Cancer Centers.

**Application Due Date:** January 29, 2018

Learn More >>

**Recent Publications**

The tumor genome in human immunodeficiency virus-related head and neck cancer: Exploitable targets?
Burtness B.
Survival of pancreatic cancer cells lacking KRAS function.
Muzumdar MD, Chen PY, Dorans KJ, Chung KM, Bhutkar A, Hong E, Noll EM, Sprick MR, Trumpp A, Jacks T.

Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016.

Metabolite and Microbiome Interplay in Cancer Immunotherapy.
Johnson CH, Spilker ME, Goetz L, Peterson SN, Siuzdak G.
Cancer Res. 2016 Nov 1;76(21):6146-6152.

Metabolomics guided pathway analysis reveals link between cancer metastasis, cholesterol sulfate, and phospholipids
Cancer & Metabolism2017:9

Knowledge and beliefs regarding cervical cancer screening and HPV vaccination among urban and rural women in León, Nicaragua.
Rees HD, Lombardo AR, Tangoren CG, Meyers SJ, Muppala VR, Niccolai LM.

Prostate cancer outcomes for men aged younger than 65 years with Medicaid versus private insurance.
Mahal AR, Mahal BA, Nguyen PL, Yu JB.
Video-assisted thoracic surgery and open chest surgery in lung cancer treatment: present and future.
Detterbeck F, Molins L.

Humanized mouse model supports development, function, and tissue residency of human natural killer cells.

DNA Mismatch Repair Deficiency Promotes Genomic Instability in a Subset of Papillary Thyroid Cancers.
Javid M, Sasanakietkul T, Nicolson NG, Gibson CE, Callender GG, Korah R, Carling T.

Fate of Pneumonectomy Patients Variably Captured by Non-Small Cell Lung Cancer Staging System.
Dhanasopon AP, Salazar MC, Hoag JR, Rosen JE, Kim AW, Detterbeck FC, Blasberg JD, Boffa DJ.

Regional Medicare Expenditures and Survival Among Older Women With Localized Breast Cancer.

Tumor microvessel density as a prognostic marker in high-risk renal cell carcinoma patients treated on ECOG-ACRIN E2805.
The eighth edition TNM stage classification for lung cancer: What does it mean on main street?
Detterbeck FC.
Read More >>

The cellular endosomal protein stannin inhibits intracellular trafficking of human papillomavirus during virus entry.
Read More >>

Patterns of care and outcomes for use of concurrent chemoradiotherapy over radiotherapy alone for anaplastic gliomas.
Yeboa DN, Rutter CE, Park HS, Lester-Coll NH, Corso CD, Mancini BR, Bindra RS, Contessa J, Yu JB.
Read More >>